RE: Prediction31 Aug 2023 08:43
Just need to read RNS, before making dismissive comments lol
Following receipt of the Study results, Ovoca will complete a detailed investigation of the Study datasets and, based on the findings from these further investigations, will determine the appropriate future strategy regarding the development of Orenetide, including whether the Company should continue with its development of the product, and any implications this may have for the wider strategy of the Company. Further announcements will be made as and when appropriate. As at 31 July 2023, Ovoca has an unaudited cash balance of EUR2.6 million.